InvestorsBoard of Directors

Dr Paul Harper, Chairman

Dr Paul Harper, Chairman

Dr Paul Harper has over 30 years' experience in the life sciences industry covering both drug development and medical devices. He is Chairman of Physiomics plc, Sareum plc, Angel Biotechnology Holdings plc and Director of Reneuron Holdings plc, all AIM quoted companies.  In addition, he is chairman of FDAS Ltd, and Monica Healthcare Ltd. Paul has served as Chief Executive of Cambridge Antibody Technology Limited, and founded Provensis Limited. He has also served as Corporate Development Director of Unipath Limited, then the medical diagnostics business of Unilever PLC, and as Director of Research and Development for Johnson & Johnson Limited. Formerly head of Antimicrobial Chemotherapy for Glaxo PLC, Paul has a PhD in Molecular Virology and is the author of over 50 publications.

   
JM_TN

Dr Jim Millen, Chief Executive Officer

Jim joined Physiomics in April 2016, bringing over 15 years’ experience in pharmaceuticals and biotechnology gained at a number of blue chip global companies as well as smaller UK-based organisations. At Allergan, Jim was responsible for corporate development in its Europe, Africa and Middle East region where he was pivotal in expanding the company’s geographical footprint before moving to a senior role responsible for commercial strategy and market access. Prior to that, at GSK, Jim held business development roles of increasing responsibility including within the company’s innovative Centre of Excellence for External Drug Discovery. In the last 18 months Jim has supported a number of smaller companies in fund raising and strategic partnering activities. Over the course of his career he has completed an array of deals worth many hundreds of millions of dollars, spanning licencing, acquisition, divestment, development and commercialisation.

Jim studied medicine at Queens’ College, Cambridge University and qualified as a doctor from the London Medical School. He holds an MBA from INSEAD.

   
Dr Christophe Chassagnole, Chief Operating Officer

Dr Christophe Chassagnole, Chief Operating Officer

Dr Christophe Chassagnole has been involved in systems biology and bio-computing projects since the mid-nineties, with experience in both academic and industrial environments. His Doctorate was achieved at the Victor Segalen-Bordeaux II University, and then he held a post doctorate position with IBVT at Stuttgart University. Before Joining Physiomics Dr Chassagnole worked in France as a senior researcher for CRITT Bio-Industries (Toulouse) for 3 years. He joined Physiomics in May 2004 as project leader to develop the model portfolio of the company. He was appointed Chief Operating Officer of Physiomics in May 2007.